Abstract:The medical model of obesity treatment--combining diet, exercise, and behavior modification with antiobesity agents--suffered a setback when fenfluramine and dexfenfluramine were withdrawn from the market because of an association between these medications and valvular regurgitation. The Food and Drug Administration has recently approved sibutramine (Meridia), a norepinephrine and serotonin reuptake inhibitor that was originally developed as an antidepressant, but which has also been shown to reduce weight. In a 1-year placebo-controlled trial, 65% of patients receiving 15 mg sibutramine daily lost more than 5% of their body weight, compared with 29% of patients receiving a placebo; 39% of patients in the sibutramine group lost more than 10% of their body weight, compared with 8% of patients in the placebo group. Health benefits observed in patients receiving sibutramine include reductions in levels of triglycerides, uric acid, total cholesterol, and low-density lipoprotein (LDL) cholesterol and an increase in high-density lipoprotein (HDL) cholesterol levels. Another antiobesity drug currently under review by the Food and Drug Administration is orlistat (Xenical), a pancreatic lipase inhibitor that reduces the absorption of dietary fat by approximately 30%, thus reducing energy intake. In a 1-year placebo-controlled trial, 55% of patients receiving orlistat lost more than 5% of their body weight, and 25% lost more than 10% of their body weight, compared with 33% and 15%, respectively, of patients in the placebo group. In addition, orlistat slowed the rate of weight regain in the second year of treatment. Health benefits demonstrated in clinical trials of orlistat include reduced LDL cholesterol levels and increased levels of HDL cholesterol, reduced blood pressure and fasting insulin levels, improved oral glucose tolerance test outcomes, and improved glycemic control in obese patients with diabetes. The future of the pharmacologic treatment of obesity is promising. Many new antiobesity agents are in the early stages of development, and our understanding of the body's weight-regulating mechanisms is advancing steadily. Human trials of recombinant leptin are underway. Other promising compounds include those that block the Neuropeptide Y5 and Y1 (NY5, NY1) and Melanocortin-4 (MC4) receptors, stimulate uncoupling proteins, and unbind corticotrophin-releasing factor from its binding protein. As better medical treatments for obesity become available, the focus in dietary prescription may shift away from reducing energy intake toward healthier eating for disease prevention. At present, a comprehensive approach, which, in some patients, may include medical therapy as an adjunct, is necessary to treat obesity effectively.

Metabolic alliance: pharmacotherapy and exercise management of obesity

New insights into the treatment of obesity.

Contemporary medical, device, and surgical therapies for obesity in adults

Weight Loss Pharmacotherapy: Current and Future Therapies

The role of incretin receptor agonists in the treatment of obesity

[Pharmacological treatment of obesity. Current situation and new treatments]

The incretin/glucagon system as a target for pharmacotherapy of obesity

Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management

Exercise as a Therapeutic Strategy for Obesity: Central and Peripheral Mechanisms

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Modern medical management of obesity: the role of pharmaceutical intervention

Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity

Pharmacotherapy for obesity: moving towards efficacy improvement

Transforming obesity: The advancement of multi-receptor drugs

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

Latest approaches for the treatment of obesity

Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions

Evolving Approaches for Pharmacological Therapy of Obesity

Future directions in obesity pharmacotherapy